SCHEMBL977523

SCHEMBL977523

O=C(/C=C/c1ccccc1)c1cccc(C(F)(F)F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 1.00
CYP1B1 Q16678 3/20 0.70
CYP1A1 P04798 1/20 0.70
P4HB P07237 3/20 0.66
PLIN1 O60240 1/20 0.62
LMNA P02545 1/20 0.62
BCHE P06276 1/20 0.62
MAPT P10636 1/20 0.62
TNFRSF1A P19438 1/20 0.62
ACHE P22303 1/20 0.62
RECQL P46063 1/20 0.62
PLIN5 Q00G26 1/20 0.62
ABHD5 Q8WTS1 1/20 0.62
ALDH1A1 P00352 1/20 0.61
CES2 O00748 1/20 0.56
CTSL P07711 1/20 0.55
CTSB P07858 1/20 0.55
HDAC3 O15379 1/20 0.55
HDAC4 P56524 1/20 0.55
HDAC1 Q13547 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL977524 1.00 MAOB (1.00) MAOBCYP1B1CYP1A1P4HBPLIN1
SCHEMBL2646709 0.92 MAOB (0.84) MAOBCYP1B1CYP1A1P4HBPLIN1
SCHEMBL2665141 0.92 MAOB (0.84) MAOBCYP1B1CYP1A1P4HBPLIN1
SCHEMBL9779396 0.91 MAOB (0.83) MAOBCYP1B1CYP1A1P4HBPLIN1
SCHEMBL3032561 0.91 MAOB (0.83) MAOBCYP1B1CYP1A1P4HBPLIN1
SCHEMBL8808974 0.87 MAOB (0.77) MAOBCYP1B1CYP1A1P4HBMAPT
SCHEMBL8808970 0.87 MAOB (0.77) MAOBCYP1B1CYP1A1P4HBMAPT
SCHEMBL30504740 0.84 MAOB (0.72) MAOBCYP1B1CYP1A1P4HBALDH1A1
SCHEMBL11942091 0.84 P4HB (0.78) MAOBCYP1B1CYP1A1P4HBLMNA
SCHEMBL24264943 0.84 MAOB (0.70) MAOBCYP1B1CYP1A1P4HBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116284114-A Method for synthesizing chiral 1, 3-phosphine alcohol 陕西师范大学 2023-06-23 CN disclosed
US-8754179-B2 Light activated shape memory co-polymers CORNERSTONE RESEARCH GROUP, INC. (US) 2014-06-17 US disclosed
EP-1928827-B1 PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS MYRIAD GENETICS INC (US) 2012-08-22 EP disclosed
US-8217073-B2 Pyrrole derivatives as therapeutic compounds MYREXIS, INC. (US) 2012-07-10 US disclosed
US-7872029-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP 2011-01-18 US disclosed
US-20100216862-A1 Pyrrole Derivatives As Therapeutic Compounds MYRIAD PHARMACEUTICALS, INC. (US) 2010-08-26 US disclosed
US-7714022-B2 Pyrrole derivatives as therapeutic compounds MYRIAD PHARMACEUTICALS, INC. (US) 2010-05-11 US disclosed
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Robinson, Thomas Philip (US) 2009-01-15 US disclosed
US-20080249158-A1 PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS MYRIAD GENETICS, INCORPORATED (US) 2008-10-09 US disclosed
US-7432303-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Bowen, J. Phillip (US) 2008-10-07 US disclosed
US-20080021166-A1 Light Activated Shape Memory Co-Polymers GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE 2008-01-24 US disclosed
EP-1799771-A2 LIGHT ACTIVATED SHAPE MEMORY CO-POLYMERS CORNERSTONE RESEARCH GROUP, INC. (US) 2007-06-27 EP disclosed
WO-2007001407-A2 LIGHT ACTIVATED SHAPE MEMORY CO-POLYMERS CORNERSTONE RESEARCH GROUP, INC. (US) 2007-01-04 WO disclosed
US-6906105-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states BOWEN J PHILLIP (US) 2005-06-14 US disclosed
US-6462075-B1 USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2002-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018167-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, FLT4, VEGFA MAOB 2526/4885CYP1B1 747/4885CYP1A1 649/4885
US-20100216862-A1 Pyrrole Derivatives As Therapeutic Compounds APP, PSEN2, PSEN1 MAOB 2093/4885CYP1B1 4542/4885CYP1A1 4761/4885
US-20080249158-A1 PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS APP, PSEN2, PSEN1 MAOB 2093/4885CYP1B1 4542/4885CYP1A1 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.